...
首页> 外文期刊>Developmental Immunology: Journal of Immunology Research >Thr92Ala Polymorphism of Human Type 2 Deiodinase Gene (hD2) Affects the Development of Graves' Disease, Treatment Efficiency, and Rate of Remission
【24h】

Thr92Ala Polymorphism of Human Type 2 Deiodinase Gene (hD2) Affects the Development of Graves' Disease, Treatment Efficiency, and Rate of Remission

机译:人类2型脱碘酶基因(hD2)的Thr92Ala多态性影响Graves病的发展,治疗效率和缓解率

获取原文
           

摘要

Clinical symptoms vary in thyrotoxicosis, and severity of these depends on many factors. Over the last years, impact of genetic factors upon the development and clinical significance of thyrotoxic symptoms became evident. It is known that a production of T3 in various tissues is limited by deiodinase 2 (D2). Recent studies revealed that certain single nucleotide polymorphisms (including threonine (Thr) to alanine (Ala) replacement in D2 gene codon 92, D2 Thr92Ala) affect T3 levels in tissues and in serum. Individuals with Ala92Ala genotype have lower D2 activity in tissues, compared with that in individuals with other genotypes. In our study, we have assessed an association of D2 Thr92Ala polymorphism with (1) frequency of disease development, (2) severity of clinical symptoms of thyrotoxicosis, and (3) rate of remissions, in Graves' disease patients.
机译:甲状腺毒症的临床症状有所不同,其严重程度取决于许多因素。在过去的几年中,遗传因素对甲状腺毒性症状的发展和临床意义的影响变得显而易见。已知在各种组织中T3的产生受到脱碘酶2(D2)的限制。最近的研究表明,某些单核苷酸多态性(包括D2基因第92位密码子,D2 Thr92Ala中的苏氨酸(Thr)转变为丙氨酸(Ala))会影响组织和血清中的T3水平。与具有其他基因型的个体相比,具有Ala92Ala基因型的个体在组织中的D2活性较低。在我们的研究中,我们评估了Graves病患者D2 Thr92Ala多态性与(1)疾病发展频率,(2)甲状腺毒症的临床症状严重程度和(3)缓解率之间的相关性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号